David R. Strutton is Vice President of Global Pharmaceuticals and Policy Evidence Research in Merck’s Center for Observational and Real-World Evidence (CORE). David’s organization has global responsibility for developing the integrated evidence strategy, including HTA/ reimbursement and overall real-world evidence strategies to support global access to Merck’s in-line and pipeline global pharmaceutical products, as well as to address the evidence needs of patients, payers, health systems, and clinicians. As the CORE lead for Policy Evidence Research, David’s organization is responsible for generating and disseminating evidence to support policy objectives regarding health technology assessment (HTA), pricing and reimbursement, healthcare system inefficiencies, affordability and health care quality; as well as aligning product-specific policy issues with evidence-generation strategies and generating scientific and credible HTA review responses.
Prior to joining Merck, David was most recently Vice President for Vaccines Global Health and Value at Pfizer. In this role, David was responsible for research programs demonstrating the public health and economic value of vaccines, as well as the development of global market access and pricing strategies and outcomes research studies that led to accelerated and sustained reimbursement for national immunization programs throughout the world.
David was also involved in establishing the long-term commitment to supply PCV13 at affordable and sustainable prices to GAVI-eligible countries, under an initiative part-funded by the Bill and Melanie Gates Foundation.
The first decade of David’s career was spent as a health economics and outcomes research consultant to the pharmaceutical industry, working across therapeutic areas and geographic locations both developing market access strategies and conducting outcomes research.
David received his BA from the University of Rochester, his MPH from The George Washington University, and his PhD in Health Economics from the Johns Hopkins University Bloomberg School of Public Health. David has authored over 100 publications and presentations and has had an adjunct faculty appointment at the Johns Hopkins University Bloomberg School of Public Health since 2005.